- WKN: A14KEB
- ISIN: DE000A14KEB5
- Land: Deutschland
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
28. November 08:00 E-Mobilität Batterie Index: Unaufhaltsam
28. November 08:19 DAX-Wochenausblick: Omikron verdirbt die Jahresendrally – oder?
28. November 08:30 TSI USA: 100 Prozent Plus? Keine Besonderheit!
28. November 09:29 Mit System zu den Top-Performern wie Tesla oder Nvidia
28. November 10:00 Biotech-Kursexplosion voraus – dieser Hot-Stock bläst jetzt zum ...
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021